Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...
Reports Q4 revenue $73.0M, consensus $72.7M. “In 2024, we successfully executed on our strategic growth initiatives, achieving record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback